Detalles de la búsqueda
1.
Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.
Proc Natl Acad Sci U S A
; 120(5): e2208960120, 2023 Jan 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-36689660
2.
The ribosomal S6 kinase 2 (RSK2)-SPRED2 complex regulates the phosphorylation of RSK substrates and MAPK signaling.
J Biol Chem
; 299(6): 104789, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37149146
3.
ERK1/2 inhibitors act as monovalent degraders inducing ubiquitylation and proteasome-dependent turnover of ERK2, but not ERK1.
Biochem J
; 480(9): 587-605, 2023 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37018014
4.
RAS interaction with Sin1 is dispensable for mTORC2 assembly and activity.
Proc Natl Acad Sci U S A
; 118(33)2021 08 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-34380736
5.
Lysine acetylation controls local protein conformation by influencing proline isomerization.
Mol Cell
; 55(5): 733-44, 2014 Sep 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-25127513
6.
SLFN11 informs on standard of care and novel treatments in a wide range of cancer models.
Br J Cancer
; 124(5): 951-962, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33339894
7.
Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation.
J Cell Sci
; 127(Pt 4): 788-800, 2014 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24363449
8.
The increase in BIK expression following ERK1/2 pathway inhibition is a consequence of G1 cell-cycle arrest and not a direct effect on BIK protein stability.
Biochem J
; 459(3): 513-24, 2014 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24527759
9.
Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer.
Biochem Soc Trans
; 42(4): 776-83, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25109957
10.
The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance.
Biochem J
; 450(2): 285-94, 2013 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23234544
11.
Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.
Nat Commun
; 15(1): 477, 2024 Jan 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38216572
12.
RAS-dependent RAF-MAPK hyperactivation by pathogenic RIT1 is a therapeutic target in Noonan syndrome-associated cardiac hypertrophy.
Sci Adv
; 9(28): eadf4766, 2023 07 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37450595
13.
Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling.
Biochem Soc Trans
; 40(1): 73-8, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22260668
14.
Resistance to ERK1/2 pathway inhibitors; sweet spots, fitness deficits and drug addiction.
Cancer Drug Resist
; 2(2): 365-380, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-35582726
15.
Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors.
Nat Commun
; 10(1): 5167, 2019 11 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-31727888
16.
MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance.
Nat Commun
; 10(1): 2030, 2019 05 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31048689
17.
Control of cell death and mitochondrial fission by ERK1/2 MAP kinase signalling.
FEBS J
; 284(24): 4177-4195, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28548464
18.
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road.
Nat Rev Cancer
; 15(10): 577-92, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26399658
19.
That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance.
Br J Pharmacol
; 169(8): 1708-22, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23647573
20.
A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook.
Sci Signal
; 4(170): er2, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21674991